Please login to the form below
Remestemcel-L
This page shows the latest Remestemcel-L news and features for those working in and with pharma, biotech and healthcare.
Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study
Remestemcel-L was being studied in patients with COVID-19-related acute respiratory distress. ... Remestemcel-L was being studied in ventilator-dependent COVID-19 patients with moderate-to-severe acute respiratory distress (ARDS).
Latest news
-
Mesoblast expands compassionate use COVID-19 programme
The drug, an allogeneic mesenchymal stem cell (MSC) product candidate dubbed remestemcel-L, will now be available for children between the ages of two months and 15 years old infected with ... Remestemcel-L is comprised of culture-expanded mesenchymal
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- AstraZeneca blocks take-private buyout of Sobi
- Lilly’s combination antibody expanded to children under 12
- Working with purpose and putting talent development at the heart of operations
- A Lucid Thirsty Thursday D&I Special
- Diversity in clinical trials: looking back at our 2021 blogs
- MHRA approves second COVID-19 antibody treatment
- First trial of a vaccine against Alzheimer’s launches
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Pfizer's 2021 revenue predictions soar to $82bn
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
